Press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jul 12, 2021David F. Melcher to be non-executive chair; Claire Pomeroy, MD, MBA, to be a director
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that David F. Melcher will be non-executive chair of the board of directors, and Claire...
-
Jun 22, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2020 Sustainability Report, highlighting significant achievements in environmental,...
-
Jun 11, 2021
USA Swimming, the national governing body for the sport of swimming in the United States, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, have...
-
Jun 8, 2021Company Now Supplying More Than 40 Countries for Pandemic Vaccination Campaigns
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling 2 billion...
-
May 18, 2021New plant will produce drug delivery devices, employ 150 people in 2024 and up to 600 when full operations start in 2030
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will build a €165 million ($200 million USD) high-tech manufacturing facility in the city of...
-
May 13, 2021BD Onclarity™ HPV Assay CE Marked for Self-Collection; Available on BD Viper™ LT and BD COR™ Systems
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the industry's first self-collection claim for HPV screening has been CE marked to the...
-
May 6, 2021- Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.9 billion for the second fiscal quarter ended March 31, 2021....
-
May 6, 2021Standalone Diabetes Care business expected to leverage position as global leader in insulin delivery and expand presence in large and high-growth diabetes market
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized management to proceed with a plan to...
-
Apr 27, 2021
CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit...
-
Apr 23, 2021
USA Track & Field (USATF) and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, have partnered to provide rapid COVID-19 testing for USATF athletes at...
-
Apr 13, 2021WHO Rapid Communication cites high accuracy for the detection of TB, rifampicin and isoniazid resistance on respiratory samples
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD MAX™ Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay was...
-
Apr 1, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona...
-
Apr 1, 2021BD Veritor™ Plus System supports return-to-school and return-to-work programs through serial testing
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization...
-
Mar 30, 2021New Test on the BD Veritor™ Plus System Can Detect SARS-CoV-2, Influenza A, Influenza B from Single Patient Sample
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA)...
-
Mar 17, 2021
FRANKLIN LAKES, N.J. (March 17, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the U.S....
-
Mar 9, 2021Reporting app helps facilitate SARS-CoV-2 testing and result reporting from BD Veritor™ Plus System
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced an agreement with ImageMover, a software platform that automates and simplifies medical...
-
Feb 22, 2021Aims to Pair BD Antigen Test with Scanwell Health Mobile App
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Scanwell Health, a leader in smartphone-enabled at-home medical tests, today announced a...
-
Feb 12, 2021New single test for the BD MAX™ System also shows ability to detect U.K., South African Variants
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use...
-
Feb 4, 2021- First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter ended December 31,...
-
Feb 3, 2021In conjunction with clinical findings and the results of other laboratory testing, BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes may help clinicians determine the risks of Intubation with Mechanical Ventilation and also of mortality in COVID-19 patients, aiding in patient management decisions
EYSINS, Switzerland, (Feb. 3, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark of BD Multitest™ 6-Color TBNK...
-
Jan 26, 2021Polen to Succeed Vince Forlenza Effective April 28
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of...
-
Jan 25, 2021Peer-Reviewed Study Suggests BD Antigen Test Likely to Be More Selective at Detecting Patients Who Are Shedding Infectious SARS-CoV-2 Virus
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a peer-reviewed study that shows BD's antigen test may be more...
-
Jan 12, 2021- Preliminary first fiscal quarter 2021 revenues of $5.3 billion grew 25.6% on a reported basis. On a currency-neutral basis, revenues increased 24.2%, driven by higher base revenues in all three segments and COVID diagnostic revenues.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal quarter ended Dec. 31,...
-
Dec 16, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling more than 1...
-
Dec 14, 2020
FRANKLIN LAKES, N.J. (Dec. 14, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released its inaugural cybersecurity annual report,...
-
Nov 24, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, an increase of 5.1% from the previous quarter. The dividend...
-
Nov 23, 2020Reports Generated by BD Synapsys™ 3.84 Informatics Solution Simplify Mandatory Public Health Reporting
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be...
-
Nov 10, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus...
-
Nov 5, 2020- Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.784 billion for the fourth fiscal quarter ended September 30,...
-
Nov 2, 2020The first shipment of 1.2 million SARS-CoV-2 Assays for use on the BD Veritor™ Plus System to be delivered in The Netherlands by mid-November
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the receipt of an order from the Dutch Ministry of Health for 9.2 million of its rapid,...
-
Oct 22, 2020Patrick Kaltenbach appointed chief technology officer
Dave Hickey promoted to president, Life Sciences segmentBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology...
-
Oct 21, 2020
CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR...
-
Oct 16, 2020BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes brings time-tested immune assessment solution to European clinicians treating COVID-19 patients
EYSINS, Switzerland, Oct. 16, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark and European availability of a...
-
Oct 7, 2020Global Mercy will deliver free, world-class surgical care to patients in African nations who lack healthcare access
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, this year celebrates its 25 year of philanthropic partnership with the global nonprofit, Mercy Ships,...
-
Sep 30, 2020SARS-CoV-2 Assay for BD Veritor™ Plus System to be available in Europe by end of October
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus...
-
Sep 15, 2020
FRANKLIN LAKES, N.J. (Sept. 15, 2020) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: BD is aware that a...
-
Sep 9, 2020Results show clinical study design may influence performance estimates and published sensitivity claims of SARS-CoV-2 antigen tests
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new research study that demonstrated performance of the BD Veritor™...
-
Aug 10, 2020
BD (NYSE: BDX), a leading global medical technology company, together with the BD Foundation, its charitable affiliate, today committed $7.8 million in monetary grants and product donations over...
-
Aug 6, 2020- As reported, revenues of $3.855 billion decreased 11.4 percent
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.855 billion for the third fiscal quarter ended June 30, 2020....
-
Jul 30, 2020Capital investments will enable U.S. manufacturing of 8 million BD Veritor™ brand SARS-CoV-2 tests per month
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $24 million investment from the U.S. Department of Defense in collaboration with the...
-
Jul 21, 2020U.S. Orders 140 Million Additional Devices; Canada Orders 37 Million Additional Devices
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional pandemic orders for needles and syringes from the United States and Canada...
-
Jul 15, 2020Government committed to use of BD Veritor™ Plus System and 15-minute SARS-CoV-2 test kits
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today a commitment from the U.S. Department of Health and Human Services (HHS) to purchase BD...
-
Jul 8, 2020Company Finalizes Initial Pandemic Order for 50 Million Injection Devices to Support Operation Warp Speed Vaccination Program
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced...
-
Jul 6, 2020- Simple new assay leverages more than 25,000 BD Veritor™ instruments already used across the U.S. to immediately increase access to COVID-19 testing in frontline health care settings
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization...
-
Jul 3, 2020
CME America, a wholly owned subsidiary of BD (Becton, Dickinson and Company), announced a voluntary recall for all CME America BodyGuard® Infusion System Administration Sets (infusion...
-
Jul 3, 2020First Shipments of Injection Devices Already Arrived in U.K.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the receipt of a large pandemic order from the U.K. government for 65 million needles...
-
May 21, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has priced its previously announced registered offerings of $1.5 billion of common stock, par value $1.00 per share, at a...
-
May 19, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has commenced registered offerings of $1.5 billion of common stock, par value $1.00 per share, and $1.5 billion of depositary...
-
May 7, 2020- As reported, revenues of $4.253 billion increased 1.4 percent
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.253 billion for the second fiscal quarter ended March 31, 2020....
-
Apr 27, 2020Recalls for BodyGuard® Infusion Pumps and Certain Lots of CMEAmerica BodyGuard® Microsets Designated as Class I Recalls
CME America, a wholly owned subsidiary of BD (Becton, Dickinson and Company), a leading global medical technology company, today issued the following update regarding two previously announced...